Saturday, September 12, 2026

The Princess Without a Title: Kim Ju-ae Trails in North Korea’s Succession Race

Former lawmaker Tae Yong-ho explains Kim Ju-ae's successor training, noting she hasn't been officially designated as heir yet.

Nuclear Power and Defense Discussed at the South Korea-Romania Summit

President Yoon Suk Yeol will hold a...

AriBio Obtains Approval to Conduct Phase 3 of Oral Alzheimer’s Disease Treatment in the UK

AriBio announced on the 26th that its...

Tag: pharmacokinetics

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Unlocking Cancer Treatment: Samsung Bioepis Achieves Keytruda Biosimilar Equivalence in Global Trials

Samsung Bioepis' biosimilar SB27 shows equivalence to Keytruda in key clinical trials, enhancing access to cancer immunotherapy.

IVL3021 vs Wegovy: The Future of Long-Acting Obesity Treatments Revealed

Inventage Lab's IVL3021 shows promising long-term obesity treatment results, outperforming competitors with effective weight maintenance strategies.

Daewoong’s Enavogliflozin Shows Consistent Glucose-Lowering Effects Across Korean and Chinese Patients

Daewoong's diabetes drug Enblo shows similar effects in Korean and Chinese patients, supporting its global expansion and future approvals.

A Long-Acting Oral Drug? Yuhan’s Latest Trial Update Is Turning Heads

Yuhan Corp's YH35995 shows promising results for Gaucher disease in Phase 1 trial, demonstrating long-lasting efficacy and BBB penetration.

SJN314: The Promising New Immunotherapy for Chronic Inflammatory Diseases in Asia

Samjin Pharmaceutical submits phase 1 trial plan for SJN314, targeting immune diseases, aiming for global partnerships in early clinical phases.

Is RPG-102 the Future of Obesity Treatment? Discover the Breakthrough Oral Solution!

ProGen and Rani Therapeutics initiate a Phase 1 trial for RPG-102, an oral obesity treatment, aiming for effective weight loss with weekly dosing.

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Tumors Shrinking, Hopes Rising: Voronoi’s VRN11 Shows Over 40% Tumor Reduction in Early Lung Cancer Trial

Voronoi's VRN11 shows promising anti-cancer efficacy in early trials, reducing tumors in resistant lung cancer patients without major side effects.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.